Literature DB >> 14734430

Respiratory syncytial virus: pervasive yet evasive.

Erica Weir1, David N Fisman.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734430      PMCID: PMC315522     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Statement on the recommended use of monoclonal anti-RSV antibody (palivizumab).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2003-09-15

2.  Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis.

Authors:  A Cade; K G Brownlee; S P Conway; D Haigh; A Short; J Brown; D Dassu; S A Mason; A Phillips; R Eglin; M Graham; A Chetcuti; M Chatrath; N Hudson; A Thomas; P A Chetcuti
Journal:  Arch Dis Child       Date:  2000-02       Impact factor: 3.791

Review 3.  Treatment of respiratory syncytial virus: antiviral therapies.

Authors:  Hasan S Jafri
Journal:  Pediatr Infect Dis J       Date:  2003-02       Impact factor: 2.129

Review 4.  Systematic review of the biology and medical management of respiratory syncytial virus infection.

Authors:  Craig Patrick Black
Journal:  Respir Care       Date:  2003-03       Impact factor: 2.258

Review 5.  Respiratory syncytial virus in healthy adults: the cost of a cold.

Authors:  Mohamed Hashem; Caroline Breese Hall
Journal:  J Clin Virol       Date:  2003-05       Impact factor: 3.168

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.